Insmed Reports Third-Quarter 2023 Financial Results and Prov

—ARIKAYCE® Total Revenue of $79.1 Million for the Third Quarter of 2023 Reflects Highest Quarter of Sales Since Launch and 17% Growth Compared to the Third Quarter of 2022—
—Company...

Related Keywords

New Jersey , United States , Japan , Japanese , Pharma Gmb , Will Lewis , Bryan Dunn , Eleanor Barisser , Mandy Fahey , Company Reiterates , Company Annual Report On Form , Exchange Commission , Drug Administration , Stage Research , Regional Poison Control Center , Prnewswire Insmed Incorporated Nasdaq , Insmed Incorporated , Corporate Communications , Total Revenue , Third Quarter , Highest Quarter , Sales Since Launch , Growth Compared , Company Reiterates Full Year , Insmed Shares Encouraging Blended , Blinded Dose Titration , Tolerability Data , Blinded Pulmonary Vascular Resistance , Topline Data , Adult Patients , Bronchiectasis Remains , Read Out , Second Quarter , Chief Executive Officer , Data Safety , Monitoring Board , Financial Guidance , Investor Relations , Nebuliser Dispersion , Nebulizer System , Hypersensitivity Reactions , Fetal Toxicity , Common Adverse Reactions , Full Prescribing , Private Securities Litigation Reform Act , Pharmakon Advisors , Orbimed Royalty , Annual Report , Markets ,